-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai issued a notice to close the purchase of some medicines, involving four medicines: Shiwei Yuquan Capsules, Biaoxu Ganmao Granules, Pediatric Promethazine Hydrochloride Tablets, and Rotondine Sulfate Injection
.
The notice shows that, according to the requirements of relevant documents, within 180 days from the date of publication and implementation of drugs applied for by medical institutions, the medical institutions that submitted the application must complete the negotiated procurement and confirm the acceptance
.
For medicines that are applied for by medical institutions but have not yet completed the procurement and acceptance, the Shanghai Pharmaceutical Office will also close the procurement status from February 17, 2022
.
In fact, since last year, Shanghai has issued a number of online purchase notices, and 18 drugs have been closed for purchase because medical institutions have not completed the negotiation and acceptance
.
It is understood that in early February last year, the Shanghai Pharmaceutical Office issued a notice to close the purchase of 13 drugs, involving Hengrui's cisatracurium besylate injection, and Chia Tai Tianqing's docetaxel injection
.
Then in March, the purchase of Wuhan Nuoan's mometasone furoate cream was closed
.
In addition to Shanghai and other provinces, all provinces have also established a network withdrawal mechanism.
In addition to closing the drugs that have not completed the negotiation purchase and acceptance, they have also carried out large-scale processing of drugs without purchase records
.
It is reported that on February 14, Jiangsu issued a notice that on March 1, the eligibility of 58 drugs to be listed on the Internet will be revoked
.
In addition, all localities have also suspended or canceled online drugs that have quality problems, discontinued production, cancellations, and have not been sold for more than one year, as well as drugs with large price differences in the same online catalog.
As few as dozens, as many as more than 10,000
.
For example, on January 18, the website of the Hunan Provincial Medical Insurance Bureau issued the "Notice on Price Correction and Price Restriction of Some Drugs" and a list of generic names of drugs, and decided to adjust the price differences in the same online catalog.
10 drugs, such as famotidine, which are relatively large (especially the large difference in the price of listing on the Internet in different periods), the price and quality are obviously inconsistent, there are many mutual complaints, and the real-name report of the price is inflated
.
And just the day before, the Sichuan Provincial Medicine and Equipment Recruitment and Procurement Center also withdrawn the 186 products that concealed the lowest listing price/bidding price (Tibet price) in the country.
.
The analysis believes that with the continuous advancement of the centralized drug procurement organized by the state, the competition among pharmaceutical companies is becoming more and more intense
.
At the same time, drug withdrawal from the Internet has long since become the norm
.
In this context, the normalization of drug withdrawals faced by pharmaceutical companies in the next few years will undoubtedly have many impacts on the future development of the pharmaceutical industry, and the pharmaceutical industry may usher in a new pattern
.
But in general, the normalization of drug withdrawal from the network is mainly to make powerful enterprises more competitive in the market through the method of survival of the fittest, and at the same time to encourage enterprises to develop and innovate
.
Therefore, the industry believes that pharmaceutical companies need to give full play to their advantages, speed up the research and development of innovative products, have competitive products with core competitiveness, do their best to evaluate consistency, and actively participate in the centralized procurement of national and provincial drugs in order to win more markets.
initiative
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The notice shows that, according to the requirements of relevant documents, within 180 days from the date of publication and implementation of drugs applied for by medical institutions, the medical institutions that submitted the application must complete the negotiated procurement and confirm the acceptance
.
For medicines that are applied for by medical institutions but have not yet completed the procurement and acceptance, the Shanghai Pharmaceutical Office will also close the procurement status from February 17, 2022
.
In fact, since last year, Shanghai has issued a number of online purchase notices, and 18 drugs have been closed for purchase because medical institutions have not completed the negotiation and acceptance
.
It is understood that in early February last year, the Shanghai Pharmaceutical Office issued a notice to close the purchase of 13 drugs, involving Hengrui's cisatracurium besylate injection, and Chia Tai Tianqing's docetaxel injection
.
Then in March, the purchase of Wuhan Nuoan's mometasone furoate cream was closed
.
In addition to Shanghai and other provinces, all provinces have also established a network withdrawal mechanism.
In addition to closing the drugs that have not completed the negotiation purchase and acceptance, they have also carried out large-scale processing of drugs without purchase records
.
It is reported that on February 14, Jiangsu issued a notice that on March 1, the eligibility of 58 drugs to be listed on the Internet will be revoked
.
In addition, all localities have also suspended or canceled online drugs that have quality problems, discontinued production, cancellations, and have not been sold for more than one year, as well as drugs with large price differences in the same online catalog.
As few as dozens, as many as more than 10,000
.
For example, on January 18, the website of the Hunan Provincial Medical Insurance Bureau issued the "Notice on Price Correction and Price Restriction of Some Drugs" and a list of generic names of drugs, and decided to adjust the price differences in the same online catalog.
10 drugs, such as famotidine, which are relatively large (especially the large difference in the price of listing on the Internet in different periods), the price and quality are obviously inconsistent, there are many mutual complaints, and the real-name report of the price is inflated
.
And just the day before, the Sichuan Provincial Medicine and Equipment Recruitment and Procurement Center also withdrawn the 186 products that concealed the lowest listing price/bidding price (Tibet price) in the country.
.
The analysis believes that with the continuous advancement of the centralized drug procurement organized by the state, the competition among pharmaceutical companies is becoming more and more intense
.
At the same time, drug withdrawal from the Internet has long since become the norm
.
In this context, the normalization of drug withdrawals faced by pharmaceutical companies in the next few years will undoubtedly have many impacts on the future development of the pharmaceutical industry, and the pharmaceutical industry may usher in a new pattern
.
But in general, the normalization of drug withdrawal from the network is mainly to make powerful enterprises more competitive in the market through the method of survival of the fittest, and at the same time to encourage enterprises to develop and innovate
.
Therefore, the industry believes that pharmaceutical companies need to give full play to their advantages, speed up the research and development of innovative products, have competitive products with core competitiveness, do their best to evaluate consistency, and actively participate in the centralized procurement of national and provincial drugs in order to win more markets.
initiative
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
